World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
110
Citations
54696
World Ranking
5473
National Ranking
2949

Overview

Robert A. Wolff is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research focuses extensively on oncology, particularly pancreatic and hepatic oncology, with considerable contributions in cancer genomics and diagnostics, colorectal cancer, and cancer immunotherapy.

The scientist's work spans multiple fields, predominantly medicine and biochemistry, genetics, and molecular biology. Their subfields include oncology, cancer research, pulmonary and respiratory medicine, surgery, and epidemiology.

Robert A. Wolff publishes frequently in well-recognized academic venues. The most common publication outlets include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Cancers
  • The Oncologist
  • Regular and Young Investigator Award Abstracts

Among their recent papers are:

  • "Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology" (2021), published in Journal of the National Comprehensive Cancer Network
  • "A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group" (2020), published in The Oncologist
  • "Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial" (2022), published in Nature Medicine
  • "CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study" (2020), published in The Lancet Oncology
  • "Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group" (2023), published in Journal of Clinical Oncology

They collaborate frequently with several researchers, including:

  • Michael J. Overman
  • Shubham Pant
  • Matthew H. G. Katz
  • Anirban Maitra
  • Jason Willis

Main topics covered by Robert A. Wolff include:

  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Neuroendocrine Tumor Research Advances
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Genetic factors in colorectal cancer

Best Publications

  • Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

    Malcolm J. Moore;David Goldstein;John Hamm;Arie Figer

  • Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer

    Navneet Dhillon;Bharat B. Aggarwal;Robert A. Newman;Robert A. Wolff

  • Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology

    Margaret A. Tempero;Mokenge P. Malafa;Mahmoud Al-Hawary;Horacio Asbun

  • Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy

    Gauri R. Varadhachary;Eric P. Tamm;James L. Abbruzzese;Henry Q. Xiong

  • Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

    Matthew H.G. Katz;Peter W.T. Pisters;Douglas B. Evans;Charlotte C. Sun

  • Pancreatic adenocarcinoma, Version 2.2021

    Margaret A. Tempero;Mokenge P. Malafa;Mahmoud Al-Hawary;Stephen W. Behrman

  • Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head

    Douglas B. Evans;Gauri R. Varadhachary;Christopher H. Crane;Charlotte C. Sun

  • Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

    James C. Yao;Alexandria T. Phan;David Z. Chang;Robert A. Wolff

  • Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas

    Maria A. Kouvaraki;Jaffer A. Ajani;Paulo Hoff;Robert Wolff

  • A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.

    Humaid O. Al-Shamsi;Waleed Alhazzani;Ahmad Alhuraiji;Eric A. Coomes

  • Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases

    Dan G. Blazer;Yoji Kishi;Dipen M. Maru;Scott Kopetz

  • Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial

    Henry Q. Xiong;Arthur Rosenberg;Albert LoBuglio;William Schmidt

  • Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma

    Chandrajit P. Raut;Jennifer F. Tseng;Jennifer F. Tseng;Charlotte C. Sun;Huamin Wang

  • Pancreaticoduodenectomy with vascular resection: margin status and survival duration

    Jennifer F. Tseng;Chandrajit P. Raut;Jeffrey E. Lee;Peter W.T. Pisters

  • Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience

    Nora A Janjan;Vincent S Khoo;James Abbruzzese;Richard Pazdur

  • Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma

    Matthew Harold Katz;Matthew Harold Katz;Huamin Wang;Jason B Fleming;Charlotte C Sun

  • Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators

    Matthew Harold Katz;Jason B Fleming;Priya R Bhosale;Gauri R Varadhachary

  • Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head

    Gauri R. Varadhachary;Robert A. Wolff;Christopher H. Crane;Charlotte C. Sun

  • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

    Scott Kopetz;Paulo M. Hoff;Jeffrey S. Morris;Robert A. Wolff

  • Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A

    Henry Q. Xiong;Arthur Rosenberg;Albert LoBuglio;William Schmidt

Frequent Co-Authors

James L. Abbruzzese
James L. Abbruzzese Duke University
Michael J. Overman
Michael J. Overman The University of Texas MD Anderson Cancer Center
Christopher H. Crane
Christopher H. Crane Memorial Sloan Kettering Cancer Center
Douglas B. Evans
Douglas B. Evans Medical College of Wisconsin
Cathy Eng
Cathy Eng Vanderbilt University
Milind Javle
Milind Javle The University of Texas MD Anderson Cancer Center
Jeffrey E. Lee
Jeffrey E. Lee The University of Texas MD Anderson Cancer Center
Jason B. Fleming
Jason B. Fleming The University of Texas MD Anderson Cancer Center
Peter W.T. Pisters
Peter W.T. Pisters The University of Texas MD Anderson Cancer Center
Huamin Wang
Huamin Wang The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While pursuing a Medical Doctor (MD) degree is a popular choice, there are many alternative career pathways in healthcare available through online programs. These options offer flexibility, affordability, and the opportunity to advance your career or specialize in related fields.

If you’re interested in healthcare leadership, consider pursuing one of the cheapest mha programs online. A Master’s in Healthcare Administration can prepare you for top management roles in hospitals and clinics.

For nurses looking to move into advanced clinical or leadership positions, the best online dnp programs provide a pathway to a terminal practice degree with hybrid and fully online options available.

Pharmacy is another in-demand field. The 3-year online pharmd programs allow working professionals or recent graduates to earn a Doctorate in Pharmacy efficiently, preparing them for clinical or research roles.

Lastly, healthcare technology is growing rapidly. A bachelor of health information management online can position you for vital roles in managing patient data and supporting hospital information systems.

Best Scientists Citing Robert A. Wolff

Trending Scientists